<DOC>
	<DOCNO>NCT00833534</DOCNO>
	<brief_summary>RATIONALE : Biological therapy , lenalidomide , may stimulate immune system different way stop cancer cell grow . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . It yet know whether lenalidomide effective without rituximab treat chronic lymphocytic leukemia small lymphocytic lymphoma . PURPOSE : This phase II trial study well lenalidomide work give without rituximab treat patient chronic lymphocytic leukemia small lymphocytic lymphoma undergone autologous syngeneic stem cell transplant .</brief_summary>
	<brief_title>Lenalidomide With Without Rituximab Treating Patients With Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Who Have Undergone Autologous Syngeneic Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate efficacy consolidation therapy comprise lenalidomide without rituximab follow maintenance therapy comprise lenalidomide patient chronic lymphocytic leukemia small lymphocytic lymphoma undergone autologous syngeneic stem cell transplantation . OUTLINE : - Consolidation phase : Patients assign 1 2 treatment group . - Group I : Patients receive oral lenalidomide daily day 1-14 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Group II : Patients receive lenalidomide group I . Patients also receive rituximab IV day start lenalidomide day 25-30 , 50-55 , 75-80 total 4 dos absence disease progression unacceptable toxicity . - Maintenance phase : Beginning 2 month completion consolidation therapy , patient receive oral lenalidomide daily day 1-21 . Treatment repeat every 28 day 18 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 28 day annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic lymphocytic leukemia ( CLL ) small lymphocytic lymphoma ( SLL ) Any stage disease Prior histological documentation CD20+ CLL SLL Has undergone autologous syngeneic stem cell transplantation comprise highdose therapy peripheral blood stem cell rescue within past 30120 day No progressive disease transplantation Has stable disease degree response transplantation No history CNS involvement PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Platelet count ≥ 50,000/mm³* ( transfusion independent ) ANC ≥ 1,500/mm³* Total bilirubin ≤ 2 mg/mL ( unless due Gilbert 's disease ) SGOT/SGPT ≤ 2.5 time upper limit normal Serum creatinine ≤ 2 mg/mL Not pregnant nursing Negative pregnancy test Fertile patient must use 2 effective method contraception least 28 day , , least 28 day completion study therapy Patients physician must register RevAssist® program willing able comply requirement RevAssist® LVEF ≥ 45 % immediately prior transplant No uncontrolled congestive heart disease No history myocardial infarction coronary artery disease No peripheral neuropathy ≥ grade 3 No allergy lenalidomide , thalidomide , allopurinol , rituximab No known hepatitis B , hepatitis C , HIV seropositivity No malignancy within past 5 year , except adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix breast No concurrent serious uncontrolled medical psychiatric illness , include serious infection NOTE : *For 5 calendar day transplant PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior CD34selected stem cell product No chemotherapy biologic therapy CLL transplant Prior rituximab administer stem cell collection allow Prior lenalidomide administer transplant allow provided patient respond lenalidomide No concurrent sargramostim ( GMCSF ) No concurrent anticancer therapy , include radiotherapy thalidomide No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
</DOC>